ONdrugDelivery Magazine asks Insight partner, Mark Tunkel to share his insights on achieving differentiation in an increasingly competitive marketplace
From game changing advances in new diabetes therapies such as Sanofi’s inhaled insulin Afrezza to the expiration of blockbuster drug patents such as GSK’s Advair – the pulmonary space in pharmaceuticals has never been more dynamic. These current developments present both opportunities and challenges to pharmaceutical innovators and generics manufacturers alike. Here, Mark Tunkel, Partner & Business Development Director, Insight Product Development, explains how companies developing and marketing inhalable pharmaceuticals can explore other strategies to improve patient outcomes over and above what the drug and device can achieve, and thus differentiate their products.